macular oedema secondary to CRVO
Ophthalmology · 2013–2014
3decisions
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| aflibercept Treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO) in patients with confirmed central retinal thickening… | Mar 2014 | Recommended with restriction | unclear |
| aflibercept Treatment of macular oedema secondary to central retinal vein occlusion (CRVO). | Nov 2014 | Recommended with restriction | input received |
| aflibercept Macular oedema secondary to central retinal vein occlusion (CRVO) in adults. | Jul 2013 | Not recommended | no section in document |
What the PBS pays
$506M in government benefit over 2024–25, across 513,292 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| aflibercept | $506.1M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.